Global CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market to Expand Rapidly with Next-Generation Therapies – BIS Research

What is CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma? 

CAR T-cell therapy is an advanced immunotherapy in which a patient’s or donor’s T-cells are genetically engineered to express chimeric antigen receptors (CARs), enabling them to recognize and attack malignant B-cells in non-Hodgkin’s lymphoma. Initially developed for third-line or later treatment, CAR T-cell therapy is now being explored in second line and frontline settings, particularly for high-risk, aggressive subtypes such as DLBCL. 

What is the Current Market Outlook for CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma? 

The outlook for CAR T-cell therapy in NHL is strong, with North America leading adoption due to a dense network of certified treatment centers, favorable reimbursement models, and established commercial therapies. Europe follows with growing uptake supported by EU approvals, while China and Asia-Pacific are expanding rapidly through domestic CAR T development and accelerated regulatory pathways. Despite high treatment costs (>$400,000 per infusion), outcomes-based pricing and risk-sharing reimbursement models are easing adoption. The CAR T-cell therapy for non-Hodgkin’s lymphoma (NHL) market is witnessing Growth as per BIS Research. 

What is the key Innovation & Trends in CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market? 

• Expansion of CAR T from third line to earlier-line therapies in NHL 
• Development of dual-targeted and armored CARs with enhanced efficacy 
• Emergence of allogeneic (off-the-shelf) CAR T platforms to address scalability and costs 
• Use of AI and digital tools for manufacturing optimization and toxicity prediction 
• Growing alignment with value-based care models and outcomes-based reimbursement 
• Integration of companion diagnostics and biomarker-driven patient selection for precision oncology 

How Does This Report Help Organizations Drive Strategic Growth? 

• Benchmark therapies – Compare autologous vs. allogeneic CAR T-cell therapy adoption. 
• Evaluate innovation pipelines – Track dual-targeted, armored, and allogeneic CARs. 
• Identify regional opportunities – Assess adoption trends across North America, Europe, Asia-Pacific, and Rest of the World. 
• Monitor strategic initiatives – Review partnerships, licensing agreements, and M&A activity in CAR T development. 
• Navigate challenges – Address cost, manufacturing scalability, toxicity risks, and regulatory bottlenecks. 

Explore Full TOC or Book a Preview  

What Are the Demand Driver and Challenges in CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market? 

Drivers 

• Rising incidence of non-Hodgkin’s lymphoma, especially DLBCL 
• High efficacy and durable remission rates in relapsed/refractory patients 
• Expanding indications into earlier lines of therapy 
• Favorable reimbursement frameworks and value-based pricing models 
• Growing clinical and R&D investment in next-gen CAR constructs 

Challenges 

• High treatment costs limiting access in low- and middle-income regions 
• Manufacturing complexity causing long vein-to-vein times 
• Limited availability of certified treatment centers globally 
• Risks of cytokine release syndrome (CRS) and neurotoxicity requiring specialized care 
• Regulatory bottlenecks delaying new CAR T approvals 

What is the Market Segmentation in the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market? 

By Indication 

•    Diffuse Large B-Cell Lymphoma 

•    Follicular Lymphoma 

•    Mantle Cell Lymphoma 

•    Others 

By Therapy 

•    Autologous CAR T-Cell Therapy 

•    Allogeneic CAR T-Cell Therapy 

By the Region 

•    North America 

•    Europe  

•    Asia-Pacific 

•    Rest of the World 

What Is the Competitive Landscape in the Chronic Myelomonocytic Leukemia Market?Key Players 

•    Allogene Therapeutics 

•    Autolus Therapeutics 

•    Bristol Myers Squibb 

•    Crispr Therapeutics 

•    Gilead Sciences 

•    Imugene 

•    Janssen Biotech 

•    Miltenyi Biomedicine 

•    Novartis AG 

•    SOTIO 

Strategic Initiatives 

Gilead/Kite is expanding Yescarta into earlier-line use and decentralizing manufacturing. Novartis is advancing dual-targeted Kymriah constructs, while BMS is broadening Breyanzi indications. Allogene and Precision BioSciences are pioneering off-the-shelf CAR T platforms to address cost and scalability, while Chinese firms like JW Therapeutics and CARsgen accelerate regional trials with regulatory support. 

Here Are Some Case Studies and Success Stories in CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market 

In the U.S., Yescarta real-world outcomes confirmed pivotal trial remission rates, strengthening payer adoption. A European study validated Breyanzi efficacy in relapsed/refractory DLBCL. In China, expedited CAR T approvals expanded access for aggressive subtypes. U.S. pilot programs using AI toxicity prediction reduced ICU admissions from cytokine release syndrome, enhancing safety and cost efficiency. 

[Schedule a Call with Industry Experts] 

[Download Complete TOC] 

Related Reports from BIS Research 

Interventional Ultrasound Market                   

Cutaneous T-Cell Lymphoma Market             

Lupus Nephritis Drugs Market                     

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.   

Contact 

Head of Marketing   

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com    

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research    

Connect with us on Twitter@ https://twitter.com/BISResearch 

Connect with us on Medium@ https://medium.com/@faisal.bis 

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc